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ORIGINAL REPORT
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SUMMARY
Purpose To show the necessity of distinguishing several patterns of drug prescribing that may lead to co-medication. It is
demonstrated how these different patterns can be investigated using large databases containing pharmacy data or
reimbursement data.
Methods Two examples illustrate how the particular pattern of co-medication studied will inﬂuence the reported
proportion of patients having co-medication, the use of antidepressants among people using anticonvulsants, and the
use of antihistamines among people receiving penicillines.
Results Depending on deﬁnition and period considered, the percentage of anticonvulsant users co-medicated with
antidepressants ranged from 5.8% (95%CI 5.0%, 6.8%) to 14.5% (95%CI 13.2%, 15.9%) in 2000. Comparing 2002 with
2000, the ratio of proportions ranged from 1.3 to 2.1. The percentage of people who received penicillines and were co-
medicated with antihistamines ranged from 0.5% (95%CI 0.4%, 0.6%) to 9.7% (95%CI 9.3%, 10.2%) in 2000. Comparing
2002 with 2000, the ratio of proportions ranged from 1.2 to 1.6.
Conclusion The co-medication patterns investigated yielded clinical as well as statistically signiﬁcant different estimates.
The estimates differed up to a factor 2.5 for the drugs usually prescribed for long periods, and a factor 12 for drugs prescribed
for short periods. Hence, we propose to distinguish the patterns ‘co-prescribing’, ‘concomitant medication,’ and ‘possibly
concurrent medication.’ The research question determines the co-medication pattern of interest, and the drug and disease
under study determine the time window. Copyright # 2006 John Wiley & Sons, Ltd.
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INTRODUCTION
The use of two or more drugs is a general concern
since efﬁcacy and safety of most drugs are
investigated for single use alone. In pharmacoepi-
demiology studies, the use of different drugs at the
same time, has served as a proxy for severity of
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disease and as a proxy for co-morbidities. Also, co-
medication has become an important concept in the
context of prescribing quality markers.1 A variety of
terms is used to refer to the use of two or more drugs
within the same time frame; co-medication, con-
comitant medication, concurrent medication, co-
administration, and multiple pharmacotherapy. Med-
line and Embase thesauruses include ‘drug combi-
nations,’ single preparations containing two or more
drugs as a ﬁxed dose, and ‘drug therapy, combi-
nation,’ two or more drugs administered separately
for a combined effect, both terms implying intended
use of two or more drugs together. Since no entry
refers to the use of two drugs regardless of whether
they are part of the same treatment, this variety of
terms seems inevitable. This labyrinth of terminol-
ogy causes problems because it hampers the
replication and full appreciation of pharmacoepide-
miology studies on a variety of issues as well as the
search for knowledge on particular combinations of
drug classes in daily clinical practice. It also
complicates systematic reviews and meta-analyses.
For example, in a review on concomitant psycho-
tropic drug use in children and teenagers, deﬁnitions
ranged from more than two psychotropic drugs being
prescribed by the same doctor on the same day to the
same patient to children who received within the
same year prescriptions for two or more psychotropic
drugs regardless of prescriber, which lead to a variety
of poorly comparable estimates.2 And a review on
gender differences in the prescribing of antipsychotic
drugs referred to patterns of co-medication with
concurrent medication, adjunct drugs, concomitant
drugs, and co-administered drugs without any
explicit deﬁnition but implied the purposeful
prescribing of two or more drugs to the same patient
allowing for different prescribers.3
Consensus is called for to be able to communicate
results unambiguously to clinicians and researchers.
For the sake of clarity, let us deﬁne co-medication as
the most general term that covers the actual taking of
two prescription drugs on the same day, regardless of
the prescribers’ intentions. Then, since not all
patterns of co-medication may be of equal interest
and not all patterns lead to the same estimates of
proportion of patients involved, several possible co-
medication patterns ought to be distinguished. We
aim to demonstrate the necessity of distinguishing
several patterns of drug prescribing that may lead to
co-medication, by illustrating the impact of different
co-medication patterns on the proportion of patients




Several patterns of co-medication can be deﬁned. In
this paper three patterns are distinguished:
1. With the preﬁx ‘co-’in the meaning of jointly,4
‘co-prescribing’ is deﬁned as ‘the jointly prescrib-
ing of more than one drug by the same prescriber
on the same day.’
2. As concomitant means concurrent,4 ‘concomitant
medication’ is deﬁned as the concurrent use of
drugs as prescribed by one or more different
medical doctors not necessarily on the same day.
Co-prescribing and concomitant medication cover
co-medication resulting from the use of drugs as
intended by medical doctors.
3. Of course, co-medication may also result from two
drugs simply being available to the patient because
they have been dispensed within a certain time
period and some left over pills may still be left in
the medicine cabinet. This latter source of co-
medication is classiﬁed as ‘possibly concurrent.’
Co-prescribing as deﬁned above would be suited to
study the quality of prescribing, for example the
prescribing of laxatives together with opioids. When
one would study the prevalence of co-morbidities
among users of any particular class of medication, the
co-prescribing pattern would most likely result in an
underestimation as patients who visit different
medical doctors would not be counted as cases of
co-medication. In this latter example, the concomitant
pattern would be best suited. Now assume the scenario
in which it is important for the pharmacist to detect all
people who may take two drugs because new
information just proved the combination to be
potentially life threatening. In this scenario, the
pharmacist would probably opt for the possibly
concurrent co-medication pattern.
Deﬁnitions made operational
Prescriptions were identiﬁed as co-prescribed if
written by the same doctor on the same day to the
same patient (Table 1). Concomitant medication was
made operational as drugs dispensed within a certain
time period while according to information available
in the pharmacy computer system, the two prescrip-
tions overlap in time. The duration of any prescription
is derived by dividing the quantity dispensed by the
daily dose prescribed as registered in the pharmacy.
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The following time windows were chosen; same day,
7 days, 15 days, and 30 days. Note that
concomitant medication allows for different prescri-
bers.
Operationally, concurrent medication is two or
more drugs under study dispensed within a certain
time period regardless of overlap between prescrip-
tions. Hence, possibly concurrent medication is
identical to (calendar) period of prevalence of a drug
among the users of another drug. Periods investigated
were month, quartile, halve a year, and year. Note that
both ‘concomitant 15 days’ dispensed and ‘possibly
concurrent–month prevalence’ have a similar study
length of 30 or 31 days.
For example, Mr Smith received a prescription for
an anticonvulsants reﬁll from his neurologist that
would last him 90 days when used according to
doctors orders. When he collected antidepressants also
prescribed by the neurologist the same day, this would
be classiﬁed as co-prescribing. However, would he
collect the antidepressants a week later, this would be
classiﬁed as concomitant. Now, assume Mr Smith’s
last anticonvulsants reﬁll that would have lasted him
90 days, was 4 months before he entered the
antidepressant prescription. This last pattern, would
be a case of ‘possibly concurrent’ with a time window
of halve a year or one full year, but not ‘possibly
concurrent’ with a time window of same month or
same quartile (see also Figure 1).
Data selection
As a source of pharmacy data The InterAction
DataBase is used.5 The InterAction DataBase is part
of the collaboration between community pharmacists
in the northern and eastern part of the Netherlands and
the Department of Social Pharmacy, Pharmacoepide-
miology and Pharmacotherapy at the University of
Groningen and comprises all prescriptions dispensed
by community pharmacies regardless of reimburse-
ment status, from 1994 up to now, and covers
anonymized prescriptions for about 450 000 people
since 1999.
As a ﬁrst index drug anticonvulsants of the ATC
category N03A entitled anticonvulsants were
chosen.6 As possible co-medication the drug group
‘antidepressants’ (ATC category N06A) was chosen,
as this combination received a lot of attention lately,
mainly in the context of the treatment of bipolar
disorder.7,8 Also, both drugs are usually intended for a
longer period of treatment whereas the second
example concerns drugs that are intended for a shorter
period of use. The second index drug class was
penicillines (ATC category J01C) with antihistamines
(ATC category R06A) as co-medication. This com-
bination was chosen because in contrast to the ﬁrst
example, both drugs are usually administered for short
periods of time. In addition, in some instances the use
of antihistamines may serve as a proxy for penicillines
allergy.9
In the ﬁrst example, the study group consisted of
people between 5 and 54 years of age who received at
least one anticonvulsant prescription in 2000. For
members of the study group all prescriptions of
anticonvulsants and antidepressants dispensed in the
year 2000 were selected. To study concomitant
medication with a time window of 1 month,
antidepressant prescriptions dispensed in December
1999 and January 2001 were also selected. Similarly, a
study group with prescriptions was retrieved for the
year 2002. Since ‘the patient’ is the level of interest in
the issue of co-medication, person is the unit of
analysis. Thus all prescription data were aggregated at
the person-level. In the second example, the study
group consisted of people in the same age range who
received at least one prescription for penicillines.
Table 1. Classiﬁcation of co-medication patterns
Pattern Co-medication
Criteria
Same prescriber Overlap Time between prescriptions
Co-prescribing Intentional Y Y Same day
Concomitant Likely — Y Same day
— Y 7 days
— Y 15 days
— Y 30 days
Possibly concurrent Possibly — — Same month
— — Quartile
— — Halve year
— — Year
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Then, all prescriptions of penicillines and antihista-
mines for the members of this study group were
selected as described above.
For all patterns of co-medication, the percentage of
people with co-medication was calculated as the
number of people who once or more ﬁt the particular
co-medication pattern divided by the number of
people having received anticonvulsants (or penicil-
lines) that same year. Ninety-ﬁve percent conﬁdence
intervals (CIs) were calculated using the ‘Pearson-
Clopper Exact method.’10 To investigate the differ-
ences in trend for the co-medication patterns from 1
year to an other year, the ratio of the proportions for 2
years (the relative prevalence) was also calculated.
It should be noted that the different point estimates
are not necessarily independent in the sense that the
members of each study group contribute to the
denominator of all point estimates in that example and
contribute differently to the nominators. Since most of
the statistical tests for the comparison of rates and
proportions cannot handle this type of data structure,
we used the crude method of conﬁdence intervals not
containing the other point estimate.
RESULTS
In the year 2000, 2701 people had received at least one
prescription for anticonvulsants. In 2002, a total of
2995 anticonvulsants people were dispensed. Depend-
ing on deﬁnition and period considered, the percen-
tage of anticonvulsant users co-medicated with an
antidepressant ranged from 6% to 14% in 2000. In
2002, these ranged from 10% to 18% (Table 2). The
relative prevalence (%2002/%2000) ranged from 1.2
to 1.9.
Table 3 shows the percentages of more than 27 000
people who received at least one prescription for
penicillines and were co-medicated with antihista-
mines. The entries in this table are smaller than those
in Table 2, reﬂecting the difference between drugs
usually prescribed for a longer period versus ones
prescribed for shorter courses. Depending on the
deﬁnition and period considered, the percentage of
penicilline users co-medicated with an antidepressant
ranged from 0.5% to 9.7% in 2000. These percentages
ranged from 0.9% to 11.2% in 2002. The relative
prevalence ranged from 1.2 to 1.6.
In general, prevalence of co-medication increased
with the time period considered. The difference
between co-prescribing and concomitant same day
could be clinically relevant but there is no statistical
reason to differentiate between these two estimates in
the presented examples (Tables 2 and 3). One would
have expected the additional demand of overlap for
classiﬁcation as concomitant to result in smaller
estimates than possibly concurrent. For the penicil-
lines and antihistamines example, this expectation
came true; concomitant 15 days and possibly
Figure 1. Co-prescribing, concomitant, and possibly concurrent medication: an example
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concurrent 1 month yielded statistically signiﬁcant
different estimates. However, this was not the case for
the anticonvulsants and antidepressants; concomitant
15 days and possibly concurrent 1 month yielded no
statistically signiﬁcant different results. The different
patterns yield not only signiﬁcant differences on the
percentage scale but also on the ratio scale. All
methods captured the trend in time, but the range in
relative prevalence was considerable.
DISCUSSION
Since co-medication is of general interest and the
variety of terminology in use obstructs clear com-
munication between clinicians and researchers, we
proposed a ﬁrst step towards unambiguous terminol-
ogy by distinguishing three deﬁnitions. We illustrated
how these different deﬁnitions may lead to both
clinically and statistically signiﬁcant different pro-
portions of people being co-medicated. The impact is
also evident when looking at the relative prevalence of
co-medication patterns, although all methods were
able to capture the time trend.
We chose deﬁnitions and patterns in such a way that
each of them is specially suited for different types of
studies. We think of co-prescribing for the study of
prescribing quality markers and severity of disease.
Concomitant medication is suited for drug utilization
studies into drug–drug combinations not investigated
together for safety and efﬁcacy and the study of co-
morbidities. Possibly concurrent medication is most
suitable when high sensitivity is demanded for, as is
the case for the study of evident safety concerns.
Clearly, the drugs of interest, the underlying ailments
Table 3. Percentage of patients receiving penicillines in 2000 (n¼ 27 149) and 2002 (n¼ 27 278) co-medicated with antihistamines
according to the deﬁnitions and time windows described, and the ratio between the percentages in these 2 years
Pattern Period
2000 2002 Ratio scale
N % 95% CI n % 95% CI % 2002 /% 2000
Co-prescribing Same day 143 0.53 0.44, 0.62 236 0.87 0.76, 0.98 1.64
Concomitant Same day 157 0.58 0.49, 0.68 260 0.95 0.84, 1.08 1.65
7 days 407 1.50 1.36, 1.65 606 2.22 2.05, 2.40 1.48
15 days 504 1.86 1.70, 2.02 750 2.75 2.56, 2.95 1.48
30 days 589 2.17 2.00, 2.35 870 3.19 2.98, 3.40 1.47
Possibly concurrent Month 630 2.32 2.14, 2.51 938 3.44 3.23, 3.66 1.48
Quartile 1137 4.19 3.95, 4.43 1616 5.92 5.65, 6.21 1.41
Half year 1827 6.73 6.43, 7.03 2231 8.18 7.86, 8.51 1.22
Year 2622 9.66 9.31, 10.2 3060 11.22 10.85, 11.60 1.16
Total penicilline users 27 149 100.0 27 278 100.0
Table 2. Percentage of patients receiving anticonvulsants in 2000 (n¼ 2701) and 2002 (n¼ 2995) co-medicated with antidepressants
according to the deﬁnitions and time windows described, and the ratio between the percentages in these 2 years
Pattern Period
2000 2002 Ratio scale
n % 95% CI n % 95% CI % 2002 /% 2000
Co-prescribing Same day 158 5.85 4.99, 6.80 312 10.42 9.35, 11.57 1.78
Concomitant Same day 166 6.15 5.27, 7.12 327 10.92 9.82, 12.09 1.78
7 days 179 6.63 5.72, 7.63 370 12.35 11.20, 13.59 1.86
15 days 216 8.00 7.00, 9.08 406 13.56 12.35, 14.83 1.70
30 days 267 9.89 8.79, 11.07 435 14.52 13.28, 15.84 1.47
Possibly concurrent Month 226 8.37 7.35, 9.48 411 13.72 12.51, 15.00 1.64
Quartile 282 10.44 9.31, 11.66 469 15.66 14.38, 17.01 1.50
Half year 349 12.92 11.68, 14.24 503 16.79 15.47, 18.18 1.30
Year 391 14.48 13.17, 15.86 531 17.73 16.38, 19.15 1.22
Total anticonvulsants users 2701 100.0 2995 100.0
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being treated, the co-morbidities of interest, and
possible safety aspects are important to consider when
deciding on the time window.
This is not just a theoretical distinction without
practical consequences as was shown in the two
examples in this paper. For the percentage of people
receiving anticonvulsants who were being co-medi-
cated with antidepressants, the point estimates
differed by a factor 2.5 (from 5.8% to 14.5%). The
point estimates were smaller for the proportion of
people receiving penicillines who were co-medicated
with antihistamines, and these estimates differed by up
to a factor 12. The relative prevalence (%2002/
%2000) also showed a clinically signiﬁcant range
from 1.2 to 1.9 for the anticonvulsants with
antidepressants, and 1.2 to 1.6 for the penicillines
with antihistamines.
To our knowledge no previous study has investi-
gated co-medication like the present study did, by
means of examples of only hypothetical interest. Few
studies went beyond the mere presenting of one
proportion and these also showed large differences in
point estimates of co-medication due to differences in
time window. One study on pharmacotherapy among
youths enrolled in Medicaid reported 13.6% of the
children receiving at least two different classes of
psychotropic drugs within a 1-week interval, and 42%
of the children when a 3-month window was used
instead.11 A study on youths treated with stimulants
that relied on pharmacy dispensing data, reported 15%
of children being co-medicated with another psycho-
tropic agent when using a 1-week interval and 21%
when a 1-year prevalence was used.12
The completeness of medication dispensing data is
essential for the study of co-medication patterns. The
advantage of pharmacy dispensing data over claims
data is that often all prescription medication is
included regardless of reimbursement status of the
particular drug. Pharmacy data will also be more
complete on prescription medication than the GP’s or
specialist’s ﬁles. However, in contrast to these, no
information on switching medication is available in
either pharmacy data or claims data. In addition,
prescriptions not presented by the patient in the
pharmacy may inﬂuence co-prescribing estimates
derived from these databases. Especially in the study
of co-medication with two drugs from the same class,
this may be a problem as switching may be
misclassiﬁed as co-medication and the other way
around.13
According to Medline’s thesaurus, co-medication
means ‘drug therapy, combination,’ where two or
more drugs administered separately for a combined
effect and demands the information on indication.
Since reliable information on indication is available in
neither pharmacy data nor claims data, ‘drug therapy,
combination’ cannot be studied by depending on these
data sources alone. However, these datasources are
very suitable for the study of ‘drug combinations,’
meaning single preparations containing two or more
active agents as a ﬁxed dose (see Medline’s thesaurus).
It should be noted that Medline’s thesaurus’ entries are
rather limited notions of co-medication since in
pharmacoepidemiology co-medication is also used as
a proxy for something that otherwise would be
extremely hard to measure. For example, co-medi-
cation has been used as an indicator for prescribing
quality,14 severity of disease,15,16 the presence of co-
morbidity,17 the prevalence of side effects,18 and so
on. So, whether or not our results are limited to
pharmacy database research, they have huge con-
sequences for research. Only after scrutinizing
deﬁnitions and time-windows it is valid to make
comparative statements like ‘co-medication with
antidepressants is less prevalent in the current study
than in the literature’ in drug utilization studies.
Similarly, statements like ‘The quality of prescribing
has improved as inhaled bronchodilators are increas-
ingly co-prescribed with inhalation corticosteroids’
and ‘The channeling of rofecoxib to patients who are
co-medicated with a drug for the cardiovascular
system suggests an overestimation of the cardiovas-
cular risk of rofecoxib compared to other NSAIDs,’
KEY POINTS
 Co-medication is a term broadly and loosely
used in clinical and epidemiology research.
 There is a labyrinth of terminology around ‘co-
medication’ that hampers the replication and
assessment of pharmacoepidemiology studies
and the search for knowledge on particular
combinations of drugs.
 Different co-medication patterns suited for
different types of research questions, need to
be distinguished.
 Different deﬁnitions of co-medication can lead
to both clinically and statistically signiﬁcant
different proportions of people being co-
medicated.
 It is both important and feasible to tailor the
operational deﬁnition of co-medication to the
research question at hand.
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can only be validly made when there is clarity about
operational deﬁnitions.
In summary, by proposing three co-medication
patterns and investigating these patterns empirically it
was shown that it is both important and feasible to
tailor the operational deﬁnition of co-medication to
the research question at hand.
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